Pharmacological inhibition of PIEZO1, MAPK, and actomyosin prevented degenerative pathology, whereas the activation of PIEZO1 increased cellular extrusion and degeneration,47 presenting viable molecular targets for the therapy of macular degeneration. The gene discussed is PIEZO1; the disease is macular degeneration.